Abion Inc (203400)

Currency in KRW
963
-125(-11.49%)
Closed·
Unusual trading volume
Trading near 52-week Low
203400 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9001,100
52 wk Range
9006,136
Key Statistics
Bid/Ask
963.00 / 971.00
Prev. Close
1,088
Open
1,066
Day's Range
900-1,100
52 wk Range
900-6,136
Volume
2.41M
Average Volume (3m)
1.07M
1-Year Change
-55.2539%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
203400 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Abion Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 15, 2026
EPS / Forecast
-73.00 / --
Revenue / Forecast
574.25M / --
EPS Revisions
Last 90 days

203400 Income Statement

Compare 203400 to Peers and Sector

Metrics to compare
203400
Peers
Sector
Relationship
P/E Ratio
−3.9x−9.5x−0.4x
PEG Ratio
−0.06−0.510.00
Price/Book
1.6x2.6x2.6x
Price / LTM Sales
96.6x9.2x3.0x
Upside (Analyst Target)
-209.3%58.1%
Fair Value Upside
Unlock24.2%8.2%Unlock

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses. It is also developing ABN701 for SEBI infectious diseases; and ABN 901, ABN 902, and ABN 903 for infectious diseases related to biological disasters. Abion Inc. was founded in 2007 and is based in Seoul, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
18.60M20.64%20.24B
Public Companies & Retail Investors
71.50M79.36%77.79B
Total
90.1M100.00%98.03B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
TELCON RF PHARMACEUTICAL. Inc.18.20%16,396,10417,838,961
Nuon Co., Ltd.2.24%2,021,4002,199,283

FAQ

What Is the Abion (203400) Stock Price Today?

The Abion stock price today is 963 KRW.

What Stock Exchange Does Abion Trade On?

Abion is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Abion?

The stock symbol for Abion is "203400."

What Is the Abion Market Cap?

As of today, Abion market cap is 86.77B KRW.

What Is Abion's Earnings Per Share (TTM)?

The Abion EPS (TTM) is -338.

From a Technical Analysis Perspective, Is 203400 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Abion Stock Split?

Abion has split 1 times.

What is the current trading status of Abion (203400)?

As of Jun 22, 2026, Abion (203400) is trading at a price of 963 KRW, with a previous close of 1,088 KRW. The stock has fluctuated within a day range of 900 KRW to 1,100 KRW, while its 52-week range spans from 900 KRW to 6,136 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.